Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03616574
Recruitment Status : Enrolling by invitation
First Posted : August 6, 2018
Last Update Posted : March 3, 2022
Information provided by (Responsible Party):
Holy Stone Healthcare Co., Ltd